Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
Dow hits new high but early gains cut, Mattel and Lyft plunge
05:39am, Wednesday, 11'th Feb 2026
10:35am: Stronger-than-expected jobs report The US labor market showed signs of strength in January, with job creation doubling expectations, even as final...
US job strength signals Fed may hold off on additional rate cuts
05:34am, Wednesday, 11'th Feb 2026
The US economy added 130,000 jobs in January, well above economists’ expectations, while the unemployment rate fell to 4.3%, signaling a labor market that...
OKYO Pharma appoints Flavio Mantelli as chief medical officer
09:39am, Tuesday, 10'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, has appointed Flavio Mantelli as its Ch
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
08:00am, Tuesday, 10'th Feb 2026
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantel
Datadog shares surge after Q4 earnings beat
07:18am, Tuesday, 10'th Feb 2026
Datadog Inc (NASDAQ:DDOG) shares jumped 16% on Tuesday after the cloud monitoring and security company reported fourth-quarter results that beat Wall Street...
OKYO Pharma appoints Flavio Mantelli as chief medical officer
04:36am, Tuesday, 10'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye...
AMD seen delivering modest Q4 beat on PC and server strength
08:27am, Monday, 02'nd Feb 2026
Advanced Micro Devices (NASDAQ:AMD) will report its fourth quarter earnings on Tuesday, with Wedbush analysts expecting a solid performance from the...
OKYO Pharma's neuropathic corneal pain study greenlit by FDA - ICYMI
11:03am, Saturday, 31'st Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week confirmed it is set to launch a Phase 2b/3 clinical trial for neuropathic corneal pain, following a productive Type C meeting with the US Food and Drug
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting
12:16pm, Friday, 30'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that an abstract on its lead
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
11:30am, Friday, 30'th Jan 2026
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting
07:13am, Friday, 30'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye...
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial
08:45am, Wednesday, 28'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from the US Food and Drug Administration (FDA) following a Type C meeting on the design of its planned Phase 2b/3 clinica
OKYO Pharma Announces Successful Type C Meeting with the FDA
07:40am, Wednesday, 28'th Jan 2026
LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial
03:43am, Wednesday, 28'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from the US Food and Drug Administration (FDA) following a Type C meeting on...
OKYO Pharma gets FDA nod for compassionate use of eye drug in neuropathic corneal pain
08:43am, Friday, 23'rd Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said on Friday the US Food and Drug Administration has authorized a single-patient expanded access, or compassionate use, investigational new drug application for its exp
